tiprankstipranks
Trending News
More News >
Suven Life Sciences Limited (IN:SUVEN)
:SUVEN
India Market
Advertisement

Suven Life Sciences Limited (SUVEN) Price & Analysis

Compare
1 Followers

SUVEN Stock Chart & Stats


Financials

SUVEN FAQ

What was Suven Life Sciences Limited’s price range in the past 12 months?
Suven Life Sciences Limited lowest stock price was ₹102.70 and its highest was ₹303.00 in the past 12 months.
    What is Suven Life Sciences Limited’s market cap?
    Suven Life Sciences Limited’s market cap is ₹63.91B.
      When is Suven Life Sciences Limited’s upcoming earnings report date?
      Suven Life Sciences Limited’s upcoming earnings report date is Aug 11, 2025 which is in 23 days.
        How were Suven Life Sciences Limited’s earnings last quarter?
        Currently, no data Available
        Is Suven Life Sciences Limited overvalued?
        According to Wall Street analysts Suven Life Sciences Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Suven Life Sciences Limited pay dividends?
          Suven Life Sciences Limited pays a Annually dividend of ₹1.382 which represents an annual dividend yield of N/A. See more information on Suven Life Sciences Limited dividends here
            What is Suven Life Sciences Limited’s EPS estimate?
            Suven Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Suven Life Sciences Limited have?
            Suven Life Sciences Limited has 218,073,720 shares outstanding.
              What happened to Suven Life Sciences Limited’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Suven Life Sciences Limited?
              Currently, no hedge funds are holding shares in IN:SUVEN

              Company Description

              Suven Life Sciences Limited

              Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
              Similar Stocks
              Company
              Price & Change
              Follow
              Aarti Drugs Limited
              Gufic Biosciences Limited
              Sequent Scientific Limited
              Sun Pharma Advanced Research Co. Ltd.
              Supriya Lifescience Limited
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis